rhEGF Treatment Improves EGFR Inhibitor-Induced Skin Barrier and Immune Defects

SIMPLE SUMMARY: In our prior study, we demonstrated that recombinant human epidermal growth factor (rhEGF) treatment is effective for managing epidermal growth factor receptor inhibitors (EGFRIs)-related skin toxicities and improves patients’ quality of life (QoL) compared with placebo. Nevertheless...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancers (Basel)
Autors principals: Kim, Ji Min, Ji, Jun Ho, Kim, Young Saing, Lee, Suee, Oh, Sung Yong, Huh, Seok Jae, Son, Choon Hee, Kang, Jung Hun, Ahn, So Yun, Choo, Jung Eun, Song, Ki-Hoon, Roh, Mee Sook
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7692663/
https://ncbi.nlm.nih.gov/pubmed/33113881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12113120
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars